View in EDS

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

Saved in:
Bibliographic Details
Title: FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
Authors: Brodowicz, T.1,2, Ciuleanu, T. E.3, Radosavljevic, D.4, Shacham-Shmueli, E.5, Vrbanec, D.6, Plate, S.7, Mrsic-Krmpotic, Z.8, Dank, M.9, Purkalne, G.10, Messinger, D.11, Zielinski, C. C.1,2
Source: Annals of Oncology. Jul2013, Vol. 24 Issue 7, p1769-1777. 9p. 1 Diagram, 4 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdt116